US equities
|
NVDA
$237.62
▲+1.57%
SPCX
$168.69
▲+6.12%
MU
$1,063.22
▼-1.09%
TSLA
$379.85
▲+2.50%
MSFT
$524.86
▲+1.42%
SNDK
$1,715.00
▼-0.29%
INTC
$117.08
▼-1.89%
META
$742.76
▲+2.02%
NVDA
$237.62
▲+1.57%
SPCX
$168.69
▲+6.12%
MU
$1,063.22
▼-1.09%
TSLA
$379.85
▲+2.50%
MSFT
$524.86
▲+1.42%
SNDK
$1,715.00
▼-0.29%
INTC
$117.08
▼-1.89%
META
$742.76
▲+2.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Aurinia Pharmaceuticals Inc.
< Previous
1
2
3
4
Next >
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
October 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
October 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
October 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
September 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
August 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
August 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
July 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
July 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
June 29, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
June 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
June 01, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
May 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces 2023 Annual General Meeting Results
May 17, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
May 09, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
May 04, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
May 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
April 25, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
April 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
April 11, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
April 05, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates
February 28, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
February 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023
February 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
< Previous
1
2
3
4
Next >
